Navigation Links
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Date:8/19/2008

SEATTLE and OSLO, Norway, Aug. 19 /PRNewswire/ -- Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human antibodies for Omeros' MASP-2 program. MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.

"This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "We are impressed by Affitech's technology, track record and personnel, and look forward to our collaboration."

Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program. Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen(TM) platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros. Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros. No further terms of the agreement were disclosed.

"We are excited about this collaboration with Omeros," said Martin Welschof, Ph.D., CEO of Affitech. "Omeros' proprietary MASP-2 program is focused on a target with broad commercial applications, and provides Affitech the opportunity to apply our expertise, human antibody library and screening platform to a non-cancer disease field. We believe that our proven technology, to
'/>"/>

SOURCE Affitech AS; Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
5. Chromos enters into an Arrangement Agreement
6. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
10. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
11. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Global Specimen Solutions, Inc. ( ... specimen management and informatics, announced today that Series ... Inc. is excited to catapult our growing momentum ... further enhance our proprietary informatics tools and infrastructure ... GSS has proved rapid market uptake of our ...
(Date:3/6/2015)... 06, 2015 Transparency Market Research has published ... Crops - Global Industry Analysis, Size, Share, Growth, Trends and ... isoxaflutole market was valued at US$ 116.3 Mn in 2013 ... expanding at a CAGR of 5.1% from 2014 to 2020. ... at 2,569.5 kilo tons in 2013. , Isoxaflutole is widely ...
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... 2015   HX360 today announced that sixteen ... HX360 Innovation Challenge competition. These companies, selected from ... chosen as one of four finalists to present their ... executives and venture capitalists during the Innovation Challenge event. ... at the 2015 HIMSS Annual Conference & Exhibition, McCormick ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... NEW YORK, June 18 In designing and conducting ... while preventing program "drift," according to Matthew Lehman, chief ... remarks at a recent seminar for biotechnology companies. ... for Success: Balancing FDA Expectations and Operational Reality," at ...
... Germany, June 18 2009 is the year of the ... cytometer - the ICP 11. , ... State Vineyard Castle Wackerbarth near Dresden. For the festive,ceremony, CEO ... society. , In 1968, the fluorescence ...
... event and prepare for it, according to new research ... that appeared today in Nature , Prof. Yitzhak ... Orna Dahan of the Institute,s Molecular Genetics Department, together ... Aviv University, examined microorganisms living in environments that change ...
Cached Biology Technology:Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar 2A Worldwide Milestone in Cell Analysis - 40 Years of Flow Cytometry 2Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... -- A new study by Georgetown University Medical Center researchers ... to stop cancer cell growth. The findings, published online ... which is mutated in a majority of families who have ... I. Yarden, PhD, assistant professor in the Department of Human ...
... A new model of the how the protein coat ... access journal BMC Biophysics , shows that ... capsid production (hierarchical assembly) can be more efficient than ... capsid enveloping a virus is essential for protection and ...
... genomic data into meaningful information about the cell is ... human biology and medicine. Researchers at the University of ... proposed a new method that creates a computational model ... protein interactions, discovering how genes and proteins connect to ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Do-it-yourself viruses: How viruses self assemble 2Toward a new model of the cell 2Toward a new model of the cell 3
... by a modification of the procedure ... Bioeng., 11 , 1055 ... yield an A 260 of ... (1 cm light path). Physical Form: ...
... White solid.. PACKAGED UNDER INERT GAS. ... reaction is "driven" to completion. A protective agent ... found in many other preparations. Blocks the lethal ... by titration. Contaminants: Heavy metals: ≤1 ...
... Basically, most ``special`` dye stains ... a few other non-routine) stains are ... of a paraffin block, staining, coverslipping ... Stain (for senile plaques) ,Bodian`s Stain ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
Biology Products: